Intellia Therapeutics (NASDAQ:NTLA) reported earnings of ($0.61) per share missing Walls Streets expectations.

Intellia Therapeutics (NASDAQ:NTLA) reported Q4 2017 earnings this Morning, coming in at ($0.61) per share, missing Wall Street’s estimates of ($0.45) per Share. Revenue for the quarter came in at $6.70 million missing the streets estimates of $8.84 million

Recent Insider Trading for Intellia Therapeutics (NASDAQ:NTLA)

  • On 1/29/2018 Caribou Biosciences, Inc., Major Shareholder, sold 550,645 with an average share price of $26.78 per share and the total transaction amounting to $14,746,273.10.
  • On 12/12/2017 Institutes For Biomed Novartis, Major Shareholder, sold 1,523,000 with an average share price of $18.30 per share and the total transaction amounting to $27,870,900.00.
  • On 12/8/2017 Nessan Bermingham, CEO, sold 336,783 with an average share price of $20.78 per share and the total transaction amounting to $6,998,350.74.
  • On 12/6/2017 Nessan Bermingham, CEO, sold 111,500 with an average share price of $20.34 per share and the total transaction amounting to $2,267,910.00.
  • On 7/11/2017 Venture Fund Ix L.P. Atlas, Major Shareholder, sold 150,000 with an average share price of $16.24 per share and the total transaction amounting to $2,436,000.00.
  • On 3/10/2017 Jean Francois Formela, Director, sold 21,132 with an average share price of $13.91 per share and the total transaction amounting to $293,946.12.



    Recent Trading for Intellia Therapeutics (NASDAQ:NTLA)
    Shares of Intellia Therapeutics closed the previous trading session at with shares trading hands.

    An ad to help with our costs